Recursion Pharmaceuticals, Inc. Revenue 2019–2025
Recursion Pharmaceuticals, Inc. annual/quarterly revenue history and growth rate from 2019 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Recursion Pharmaceuticals, Inc. revenue for the quarter ending March 31, 2026 was 6.5 M, a 56.11% decrease year-over-year.
- Recursion Pharmaceuticals, Inc. revenue for the twelve months ending March 31, 2026 was 45.6 M, a 29.63% decrease year-over-year.
- Recursion Pharmaceuticals, Inc. annual revenue for 2025 was 74.7 M, a 26.92% increase from 2024.
- Recursion Pharmaceuticals, Inc. annual revenue for 2024 was 58.8 M, a 32.00% increase from 2023.
- Recursion Pharmaceuticals, Inc. annual revenue for 2023 was 44.6 M, a 11.88% increase from 2022.
- Recursion Pharmaceuticals, Inc. annual revenue for 2022 was 39.8 M.
Recursion Pharmaceuticals, Inc. (RXRX) — Frequently Asked Questions
Recursion Pharmaceuticals, Inc. (RXRX) is a publicly traded US company. It has a market capitalization of $1.36B. In fiscal 2025 it reported revenue of $75M and net income of -$645M. Explore RXRX's stock price, financial statements, earnings history, margins and key ratios below.
What is Recursion Pharmaceuticals, Inc.'s market cap?
Recursion Pharmaceuticals, Inc. (RXRX) has a market capitalization of $1.36B.
What is the RXRX stock price?
RXRX trades at $3.04 (-5.59% on the day).
How much revenue does Recursion Pharmaceuticals, Inc. make?
Recursion Pharmaceuticals, Inc. reported revenue of $75M in fiscal 2025.
Is RXRX profitable?
In fiscal 2025, Recursion Pharmaceuticals, Inc. reported net income of -$645M.